Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SNYR | 8-K | bearish | 7/10 | Synergy CHC Corp. reported Q1 2026 revenue of $5.49M, down 32.8% YoY from $8.17M, driven by a non-repeating $1.5M licens | May 14, 2026 |
| BIIB | 8-K | bullish | 7/10 | Biogen completed its $5.3B acquisition of Apellis Pharmaceuticals on May 14, 2026, adding commercial-stage products EMPA | May 14, 2026 |
| DWTX | PRESS-RELEASE | bullish | 6/10 | Dogwood Therapeutics reported Q1 2026 EPS of -$0.15, beating consensus of -$0.20 by 25%, with no revenue. The company hi | May 14, 2026 |
| CRBP | 8-K | neutral | 4/10 | Corbus Pharmaceuticals appointed Brent Pfeiffenberger to its Board of Directors and shareholders approved an amendment t | May 14, 2026 |
| CADL | 8-K | neutral | 4/10 | Candel Therapeutics reported Q1 2026 results: net loss of $8.9M vs net income of $7.4M in Q1 2025, driven by higher R&D | May 14, 2026 |
| CINGW | 8-K | neutral | 5/10 | Cingulate Inc. reported Q1 2026 results with a net loss of $9.3M, widening from a $3.9M loss in Q1 2025, driven by a 287 | May 14, 2026 |
| BNTC | 8-K | neutral | 4/10 | Benitec Biopharma reported Q3 fiscal 2026 results with a net loss of $11.9M ($0.24/share), narrower than the year-ago lo | May 14, 2026 |
| CADL | PRESS-RELEASE | neutral | 5/10 | Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no revenue. The company hi | May 14, 2026 |
| MGTX | 8-K | bullish | 7/10 | MeiraGTx reported Q1 2026 results with a net loss of $46.3M ($0.57/share) vs $40.0M ($0.51/share) a year ago, while tota | May 14, 2026 |
| GNPX | 8-K | neutral | 4/10 | Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 (Pdx1/MafA) presented at the | May 14, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber appointed Peter M. O'Rourke Sr., former Acting Secretary of the VA and military veteran, as an independent | May 14, 2026 |
| CLNN | 8-K | mixed | 6/10 | Clene reported Q1 2026 results with total revenue of $15K (down 81% YoY from $81K) and a net loss of $8.1M ($0.69/share) | May 14, 2026 |
| CINGW | PRESS-RELEASE | neutral | 5/10 | Cingulate reported a net loss of $9.3M for Q1 2026, widening from $3.9M a year ago, driven by a surge in G&A expenses to | May 14, 2026 |
| CLNN | PRESS-RELEASE | bearish | 6/10 | Clene reported Q1 2026 EPS of -$0.69 (GAAP), a significant miss versus the -$0.50 consensus, driven by $6.0M in other ex | May 14, 2026 |
| SNYR | PRESS-RELEASE | bearish | 8/10 | Synergy CHC reported a disastrous Q1 2026: revenue collapsed 33% YoY to $5.49M (missing $8.3M consensus by 34%), EPS swu | May 14, 2026 |
| KROS | 8-K | bearish | 5/10 | Keros Therapeutics reported Q1 2026 results with a net loss of $23.7M ($1.21/share) vs net income of $148.5M ($3.66/shar | May 14, 2026 |
| MGTX | PRESS-RELEASE | bullish | 7/10 | MeiraGTx reported Q1 2026 EPS of $0.19, a 142% beat vs consensus of -$0.45, on revenue of $0.3M (well below the $17.0M c | May 14, 2026 |
| BNTC | PRESS-RELEASE | bullish | 6/10 | Benitec Biopharma reported Q3 FY2026 (March 31, 2026) net loss of $0.24/share, beating consensus of -$0.28 by 5.5%. The | May 14, 2026 |
| CMMB | PRESS-RELEASE | neutral | 4/10 | Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The com | May 14, 2026 |
| KROS | PRESS-RELEASE | bearish | 6/10 | Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue of $0.367M, 78.4% be | May 14, 2026 |
| BFRIW | 8-K | mixed | 5/10 | Biofrontera Inc. reported Q1 2026 revenue of $10.1M, up ~17% YoY from $8.6M, but slightly below the $10.3M consensus. Ne | May 14, 2026 |
| CMMB | 6-K | neutral | 5/10 | Chemomab Therapeutics reported Q1 2026 financial results, with net loss narrowing to $1.8M from $3.3M YoY on lower R&D s | May 14, 2026 |
| AUTL | 8-K | mixed | 6/10 | Autolus Therapeutics reported Q1 2026 AUCATZYL net product revenue of $26.2M, up 192% YoY from $9.0M, achieving its firs | May 14, 2026 |
| GLMD | 6-K | bullish | 7/10 | Galmed announced positive Phase 1 PK results for its oral Aramchol Meglumine (AM) formulation, showing ~500% bioavailabi | May 14, 2026 |
| CRDL | 6-K | neutral | 2/10 | Cardiol Therapeutics announced participation in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Co | May 14, 2026 |
| PYXS | 8-K | neutral | 5/10 | Pyxis Oncology reported Q1 2026 financial results, with a net loss of $23.3M ($0.37/share) vs $21.2M ($0.35/share) in Q1 | May 14, 2026 |
| CRMD | 8-K | bullish | 7/10 | CorMedix reported Q1 2026 revenue of $127.4M and GAAP net income of $38.6M ($0.43 diluted EPS), with DefenCath sales of | May 14, 2026 |
| AGMB | PRESS-RELEASE | neutral | 2/10 | Agomab Therapeutics announced that management will participate in upcoming industry and investor conferences. This is a | May 14, 2026 |
| KPTI | 8-K | mixed | 6/10 | Karyopharm reported Q1 2026 total revenue of $35.1M (up 17% YoY) and a net loss of $22.4M ($1.02 per basic share), beati | May 14, 2026 |
| FTLF | PRESS-RELEASE | mixed | 6/10 | FitLife Brands reported Q1 2026 revenue of $25.3M (+59% YoY), beating the $24.9M consensus, and EPS of $0.17 diluted, be | May 14, 2026 |